Page last updated: 2024-09-02

fingolimod hydrochloride and Neuromyelitis Optica

fingolimod hydrochloride has been researched along with Neuromyelitis Optica in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	7 (63.64)	24.3611
2020's	4 (36.36)	2.80

Authors

Authors	Studies
Audoin, B; Bensa, C; Bourre, B; De Seze, J; Januel, E; Louapre, C; Maarouf, A; Maillart, E; Moisset, X; Pelletier, J; Pique, J; Vermersch, P; Vukusic, S	1
Chou, CH; Lin, W; Lin, YK; Sung, YF; Tsai, CK; Yang, FC	1
Berthelot, E; Bonnan, M; Cabre, P	1
Nakagawa, S; Takahashi, T; Tanaka, K; Tsujino, A; Yoshimura, S	1
Buc, M	1
Fukaura, H; Izaki, S; Kubota, A; Mitsui, T; Narukawa, S; Nomura, K	1
Tanaka, K; Tanaka, M	1
Francis, CE	1
Moriya, Y; Ohnuki, T; Ryo, M; Takahashi, W; Yoshii, F	1
Kim, BJ; Lee, KH; Min, JH	1
Filippi, M; Rocca, MA	1

Reviews

4 review(s) available for fingolimod hydrochloride and Neuromyelitis Optica

Article	Year
New biological agents in the treatment of multiple sclerosis. Bratislavske lekarske listy, 2018, Volume: 119, Issue:4 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cladribine; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indans; Multiple Sclerosis; Natalizumab; Neuromyelitis Optica; Oxadiazoles; Rituximab	2018
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 9. Therapeutic progress in multiple sclerosis and neuromyelitis optica]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2013, Aug-10, Volume: 102, Issue:8 Topics: Antibodies, Monoclonal; Autoantibodies; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Secondary Prevention; Sphingosine	2013
Visual issues in multiple sclerosis. Physical medicine and rehabilitation clinics of North America, 2013, Volume: 24, Issue:4 Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Neuromyelitis Optica; Nystagmus, Pathologic; Ocular Motility Disorders; Optic Neuritis; Prognosis; Propylene Glycols; Sphingosine; Uveitis	2013
Multiple sclerosis: new measures to monitor the disease. The Lancet. Neurology, 2013, Volume: 12, Issue:1 Topics: Brain; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Sphingosine	2013

Other Studies

7 other study(ies) available for fingolimod hydrochloride and Neuromyelitis Optica

Article	Year
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:7 Topics: BNT162 Vaccine; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; SARS-CoV-2	2022
Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder. Frontiers in immunology, 2023, Volume: 14 Topics: Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuromyelitis Optica	2023
Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Multiple sclerosis and related disorders, 2021, Volume: 52 Topics: Aquaporin 4; Autoantibodies; Fingolimod Hydrochloride; France; Humans; Multiple Sclerosis; Neuromyelitis Optica	2021
FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease. Neurotoxicity research, 2021, Volume: 39, Issue:4 Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Male; Myelin-Oligodendrocyte Glycoprotein; Neuromyelitis Optica; Rats; Rats, Wistar; Sphingosine 1 Phosphate Receptor Modulators	2021
[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment]. Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:7 Topics: Aquaporin 4; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Neuromyelitis Optica; Propylene Glycols; Sphingosine	2013
Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Multiple sclerosis and related disorders, 2016, Volume: 7 Topics: Aquaporin 4; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathies; Magnetic Resonance Imaging; Middle Aged; Neuromyelitis Optica; Spinal Cord	2016
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:1 Topics: Adult; Brain; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Neuromyelitis Optica; Propylene Glycols; Sphingosine	2012